FIELD: chemistry.
SUBSTANCE: invention relates to the BRAF kinase inhibitor, which is the compound of N-(3-(5-(4-chlorophenyl)-1H-pyrazolo[3,4-b]pyridine-3-carbonyl)-2,4-difluorophenyl)propant-1-sulfonamide of formula 1.
1.
EFFECT: proposed is remedy for characterized by the BRAF kinase mutation proliferative disease, preferably melanoma, prevention or treatment.
1 cl, 2 dwg, 2 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| N-(3-(5-(4-CHLOROPHENYL)-1N-PYRAZOLO[3,4-B]PYRIDINE-3-CARBONYL)-2,4-DIFLUOROPHENYL)PROPANE-1-SULPHONAMIDE CRYSTALLINE FORM, ACTIVE COMPONENT, PHARMACEUTICAL COMPOSITION AND MEDICINE | 2018 |
|
RU2678455C1 |
| 4-OXO-3,4-DIHYDROQUINAZOLINONE COMPOUNDS FOR TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | 2021 |
|
RU2814662C1 |
| METHOD FOR PROLIFERATIVE DISEASE TREATMENT | 2012 |
|
RU2622015C2 |
| COMPOUND FOR TREATING CANCER | 2014 |
|
RU2708247C2 |
| AGENT INDUCING CELL DEATH FOR CELLS HAVING BRAF GENE MUTATIONS, AGENT SUPPRESSING GROWTH OF SUCH CELLS, AND PHARMACEUTICAL COMPOSITION FOR THE THERAPY OF DISEASES CAUSED BY GROWTH DEFECT OF SUCH CELLS | 2016 |
|
RU2760835C2 |
| NEW METHYLQUINAZOLINONE DERIVATIVES | 2020 |
|
RU2802968C1 |
| COMBINATION THERAPY | 2018 |
|
RU2815400C2 |
| CRYSTAL SALTS OF B-RAF-KINASE INHIBITOR | 2018 |
|
RU2798091C2 |
| COMBINED ANTICANCER THERAPY | 2011 |
|
RU2607596C2 |
| THERAPEUTIC COMBINATIONS CONTAINING RAF INHIBITOR AND ERK INHIBITOR | 2017 |
|
RU2774612C2 |
